DIVISION OF PATHOLOGY – Dr. Tony Magliocco, Acting Director
The goals of the Division of Pathology are to provide high quality diagnostic pathology
consultation services for all of the tumor groups and pathologists in Southern Alberta;
education in medical sciences, medial undergraduate, graduate, postgraduate and
continuing education programs; a primary research focus into the initiation and
progression of cancer, translational research and collaborative research with Cancer
Centre staff.
EDUCATION
Members of the Division are heavily engaged in teaching in medical sciences, biology
and undergraduate medicine courses, fellows and technologists, pathology,
gynecology and oncology residents and continuing education rounds. Supervision is
provided for MSc. And Ph.D. students.
CLINICAL SERVICES
Accuracy of cancer diagnosis is assessed and prognostic and management indices
are provided as requested by oncologists, to determine appropriate patient
management. Pathology findings are routinely presented at Tumor Boards in a
multidisciplinary patient management setting.
The Director of the Division promoted and provided leadership at provincial and
national levels for quality improvement in oncologic pathology through standardized
reporting of cancer diagnoses and the consistent inclusion of the pathologic variables
required for prognosis and patient management. This was achieved through the
Alberta Cancer Surgery Working Group, Canadian Association of Pathologists,
Canadian Cancer Surveillance Alliance, Laboratory Medicine Policy Advisory
Committee to the Canadian Association of Provincial Cancer Agencies and the
Staging Committee of the National Cancer Institute of Canada. National Guidelines
for Reporting Breast Cancer were developed and disseminated to all pathologists in
Canada and to other interested parties.
The pathologic data elements in the Provincial and Territorial Registries, the
Canadian Cancer Registry and the Organized Breast Cancer Screening Programs
have been upgraded through service on the Data Quality Committee of CCR and the
Working Group on the Quality Determinants Of Organized Breast Cancer Screening
Programs. Input is provided as requested by the Alberta Cancer Registry. Service is
also provided to numerous internal and external committees and organizations, e.g.
C.I.H.R., Canadian Foundation for Innovation, CRHA/CLS, U of C Ethics and
Biosafety Committees, CAP Section of Molecular Pathology, Royal College of
Physicians & Surgeons of Canada (Examination Board).
2
ACADEMIC EVENTS:
The Department Director Dr. F. Alexander retired June 30 after 22 years with TBCC,
and Dr. T. Magliocco who joined the department in 1998 fills the position as Acting
Director.
RESEARCH PERSONNEL IN DEPARTMENT
Dr. D. Demetrick's Lab
Dr. Steve Loken, Resident
Dr. Majid Akbari, Resident
Adrian Box, Grad Student
Laura Fursey, Grad Student
Linda Ganley, Grad Student
Natalie Rezansoff, Grad Student
Carol Yuen, Grad Student
Chris Meijndert, Grad Student
Monica Nguyen, Grad Student
Guido Gonzalez, Grad Student
Mary Tretiak, Grad Student
Sandy Eyton-Jones, Lab Technologist
Peter Lewkonia, Undergrad Medical Student
Dr. T. Magliocco's Lab:
Cay Egan PhD, Senior Research Associate
An-Dao Yang PhD, Senior Research Associate
Kristin Hoffman, MD Post Doctoral fellow
Martina Timm-McCann MSc. Senior Research Assistant
Susan Lee, Laboratory Technologist
Jesse McCaslin, Graduate Student , MSc Program, Medical Sciences
Jason Morris, Graduate Student, MSc Program, Medical Sciences
Anna Konscianski, Research Assistant
Andrea Mosher, Undergraduate independent study student.
PUBLICATIONS BY DEPARTMENT MEMBERS
Demetrick DJ. Targeting Cancer Treatment: the challenge of anatomical pathology to
the analytical chemist. Analyst. 2003 Aug; 128(8):995-7 Review.
Magliocco AM, Commentary (on Phase III comparison of docetaxel (D) and
paclitaxel (P) in patients with metastatic breast cancer (MBC): Notable reports
from Nottingham and ECCO), In Press Innovations in Breast Cancer Care
1(2):2003
3
Cook LS, White JL, Stuart GCE, Magliocco AM. The Reliability of Telephone
Interviews with In-person Interviews using Memory Aids. Annals of Epidemiology
2003 Aug;13(7):495-501
Magliocco AM. What does HER2 tell us in the adjuvant setting. Oncology Exchange
2003 Mar 2(2)suppl 1, 2003 20-24
Wang XD, Rosales JL, Magliocco AM, Gnanakumar R, Lee KY. Cyclin E in breast
tumors is cleaved into its low molecular weight forms by calpain. Oncogene. 2003 Feb
6;22(5):769-74
Magliocco AM. Commentary (Heterotopic ossification in rectal cancer). J Surg Oncol.
2003 Feb;82(2):137
Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in
human benign, low malignant potential, and invasive epithelial ovarian tumors.
Cancer. 2003 Jan 15;97(2):389-404
Scott S, Kimura T, Ichinohasama R, Bergen S, Magliocco AM, Reimer C, Kerviche A,
Sheridan D, DeCoteau JF.Microsatellite mutations of transforming growth factor-beta
receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic
lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter
methylation. Leuk Res. 2003 Jan;27(1):23-34
Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by
mohs micrographic surgery. J Cutan Med Surg 2003; 7:25-30.
Trotter MJ, Colwell R, Tron VA. Thrombospondin-1 and cutaneous melanoma. J
Cutan Med Surg 2003; 7:136-141.
Bruecks AK, Medlicott SA, Trotter MJ. Atypical fibroxanthoma with prominent
sclerosis. J Cutan Pathol. 2003;30:336-339.
Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, Guitart J,
Horenstein MG, Ming ME, Piepkorn MW, Rabkin MS, Reed JA, Selim AA, Trotter MJ,
Johnson MM, Shea CR. Are en face frozen sections accurate for diagnosing margin
status in melanocytic lesions? Am J Clin Pathol 2003; 120:203-208.
Toth C, Trotter M, Clark AW, Zochodne D. Mononeuropathy multiplex in association
with livedoid vasculitis. Muscle Nerve 2003; 28:634-639.
Trotter MJ, Bruecks AK. Interpretation of skin biopsies by general pathologists.
Diagnostic discrepancy rate measured by blinded review. Arch Pathol Lab Med 2003;
127:1489-92.
4
ABSTRACTS
Loken S, Nodwell M, Lester W, and Demetrick DJ. Morbidity in Immunosuppressed
Mice Treated with Reovirus (Dearing 3) as an Anti-Cancer Biotherapeutic.
International Conference on Reovirus and Cancer, Banff Alberta, March 2003.
Box A, Murthy S, Rezansoff N, and Demetrick DJ. Analysis of Cell Cycle Regulation
in the Human Cellular Response to Hypoxia. CBCRA , "Reasons for Hope", Ottawa
Ont. 2003.
Box A and Demetrick DJ. Cell Cycle Gene Regulation in the Human Cellular
Response to Hypoxia. Alberta Cancer Board Meeting, Banff, AB. Nov. 2003
Fursey L and Demetrick DJ. Comparison of INK4 family binding partners based on
differences in C-terminal structure and sequence. ACB Meeting, Banff, 2003.
Ganley L, Fursey L, Lewkonia P, Wong G, Rezansoff N, and Demetrick DJ. Human
cytosine methyltransferase regulation in cancer. Alberta Cancer Board Meeting,
Banff, AB. Nov. 2003
Loken S, Nodwell M, Lester W, and Demetrick DJ. Morbidity in Immunosuppressed
Mice Treated with Reovirus (Dearing 3) as an Anti-Cancer Biotherapeutic. Canadian
Congress of Laboratory Medicine, July 2003.
Csizmadi I., Cook L., Friedenreich C., Bryant H, Magliocco AM., Pollak M., Stratagies
to recruit women to the women’s health and hormone study (an HRT study), post
Womens Health Initiative. Canadian Breast Cancer
Research Initiative's Third National Scientific Conference, Reasons for Hope Ottawa
May 2003,
Egan C, Magliocco AM., Fujita D. AACR Special
Conference on "Advances in Breast Cancer Research." San Diego, Sept 2003
J. McCaslin, H.Cheng, D. Fujita, A. Magliocco. Evaluation of PTEN Promoter
Methylation in Breast Cancer. Poster presentation at The Alberta Cancer Board
Annual Research Meeting, 2003
J.Morris, A.Koscianski, K.Advikolanu, M.Timm-McCann, B.Shin, L.Cook,
A.Magliocco. Immunohistochemical Evaluation of WT-1 and Par-4 in Epithelial
Ovarian Cancer Using Tissue Micro-arrays. Poster presentation at the Alberta
Cancer Board, Annual Research Meeting, 2003
C. Beasley, S. Hagness, J. Booske, T. M. Breslin, F. Xu, M. J. Lindstrom, D.
Popovic, M. Okoniewski, W. Temple,
A. Magliocco, T. Ogilvie Ex-Vivo
5
Dielectric Characterization of Normal, Benign, and Malignant Breast Tissue At
Microwave Frequencies: Preliminary Results from a Multi-Institution study. IEEE
AP-S international symposium and USNC/CNC/URSI national radio science
meeting 2003 A126
J Irving, L Brown, T Magliocco, T Longacre, B Gilks, C Caldas, D Huntsman.
Amplification of a Novel BRCA2-Inactivating Gene, EMSY, in High Grade Ovarian
Carcinomas, United States and Canadian Academy of Pathology 92nd Annual Meeting
2003 A879
RT Ogilvie, PS Craighead, P Ghatage, AM Magliocco, MA Duggan, JG Nation
Assessment of Diagnostic Discrepancies Identified by Pathologic Review of
Gynecologic Oncology Patients. United States and Canadian Academy of Pathology
92nd Annual Meeting A1452: 2003
Bruecks, A.K., Kalia, S., Trotter, M.J. Expression of the cyclin-dependent kinase
inhibitors p16INK4A, p21WAF1, and p27KIP1 in seborrheic keratosis. American Society of
Dermatopathology, 50th Annual Meeting, Chicago, IL. October 9-12, 2003.
Trotter, M.J., Arlette, J.P., Kalia, S., Ciezar, S.D., Bruecks, A.K. Two distinct patterns
of p27KIP1 expression in cutaneous squamous cell carcinoma in-situ. American
Society of Dermatopathology, 50th Annual Meeting, Chicago, IL. October 9-12, 2003.
Barber, D.F., Trotter, M.J. Pagetoid cells in palmoplantar warts. American Society of
Dermatopathology, 50th Annual Meeting, Chicago, IL. October 9-12, 2003.
GRANTS
Demetrick, D. J.
Alberta Cancer Board
Histology Infrastructure Grant
$40,000. 2002-2003
Demetrick, D. J.
Cytosine Methyltransferase Regulation in Breast Cancer
Ruth Barker Foundation
$50,000. 2002-2003.
Demetrick, DJ. Structure-Function Correlates of p16-related CDK Inhibitor proteins.
2003. Alberta Cancer Board. $50,000.
Demetrick, DJ. A Novel Strategy to Evaluate the Regulation of the Hypoxic
Response of Pediatric Solid Tumour Cells. $50,000 pa. 2003-2005. Kids Cancer
Care Foundation.
6
Demetrick, DJ. Translational Proteomics. Calgary Laboratory Services/MDS.
$240,000. ($80,000 pa; 2002-2005)
Magliocco (PI), CLS health Services research funding competition, Evaluation of
novel predictive factors of Tamoxifen Resistance in breast cancer patients. $25,000
Sep 2003-April 30, 2006
Magliocco (PI) and Fujita, Alberta Cancer Board, Research Initiatives Program, Role
of c-Src in Breast Cancer $450,000 April 2003-March 2006
Duggan (PI), Magliocco and Brasher, Canadian Cancer Etiology Research Network,
Atypical Immature Metaplasia (AIM) of the Uterine Cervix: HPV, p16, and Ki-67
Profiling $19, 856.20, 2003-2004.
Cook (PI) Andrew, Duggan, Faught, Freidenreich, Magliocco. Risk factors for
molecular subtypes of endometrial cancer $444,696 total 2003-2006 Award by
Canadian Institutes of Health Research
Magliocco (PI). Alberta Cancer Board, New Equipment award $8000 (gel
documentation system) 2003
Hagness, (PI) Okinowkski, Temple, Magliocco, NIH/NCI R01 CA87007-01A2
“Dielectric Characterization of Human Breast Tissue” US$631,791 (total) 2/5/021/31/05
Magliocco (PI), Demetrick Evaluation of mechanisms and significance of PTEN loss
in Human Breast Cancer. Canadian Breast Cancer Foundation, Alberta Chapter
$92,000 2002-2004
Magliocco(PI) Duggan, Boras, Tabasari Evaluation of Value of PTEN loss in
Endometrial Biopsies CLS Research Award $9800 April 2002-2004
Magliocco (PI) Demetrick Ogilvie, Assessment of BCl2 as a surrogate marker for
Tamoxifen response in breast cancer. CLS research award $10,000 2001-2003
Cook LS (PI); Co-investigators: Csizmadi I, Pollak M, Magliocco AM, Friedenreich
CM, Bryant HE, Fick GH. The effect of oral and transdermal hormone replacement
therapy on mammographic density: The Women’s Health and Hormone Study.
Canadian Breast Cancer Research Initiative, $588,649. 2002-2005
Friedenreich (PI), LS Cook KS Courneya A Magliocco L Honoré M Duggan Biologic
determinants of the association between physical activity and endometrial cancer risk:
The role for insulin-like growth factors National Cancer Institute of Canada
$575,537.00 2002-2005
7
Demetrick (PI) Magliocco, Paterson, Translational Molecular Biology research in
breast cancer. Alberta Science and Research Authority $525,000 Jun 2000-June
2003
Alberta Cancer Board translational Laboratories Establishment fund $250,000 Gluck
PI, Magliocco and Morris Sep 2000-Aug 2003
CM Friedenreich (PI) LS Cook KS Courneya A Magliocco L Honoré M Duggan,
NCIC, Case-control study of physical activity and endometrial cancer risk. factors
NationalCancer Institute of Canada $416,619, 2001-2004